TITLE

Effect of leukotriene receptor antagonist therapy on the risk of asthma exacerbations in patients with mild to moderate asthma: an integrated analysis of zafirlukast trials

AUTHOR(S)
Barnes, Neil C.; Miller, Christopher J.; Barnes, N C; Miller, C J
PUB. DATE
June 2000
SOURCE
Thorax;Jun2000, Vol. 55 Issue 6, p478
SOURCE TYPE
Academic Journal
DOC. TYPE
journal article
ABSTRACT
No abstract available.
ACCESSION #
67206399

 

Related Articles

  • Zafirlukast: A Review of its Pharmacology and Therapeutic Potential in the Management of Asthma. Adkins, J.C.; Brogden, R.N. // Drugs;Jan1998, Vol. 55 Issue 1, p121 

    Zafirlukast is a competitive and selective leukotriene receptor antagonist indicated for the prophylaxis and treatment of chronic asthma. The rationale for the development of leukotriene antagonists was based on in vitro and in vivo data demonstrating the extensive role of the cysteinyl...

  • Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. South, Mike; Ducharme, Francine M // Internet Journal of Pediatrics & Neonatology;2005, Vol. 5 Issue 1, p31 

    This article focuses on a study whose objective was to compare the safety and efficacy of anti-leukotrienes and inhaled glucocorticoids as monotherapy in people with asthma. 13 trials, 12 in adults, one in children, met the inclusion criteria; all were in people with mild and moderate asthma....

  • Montelukast for prevention and treatment of asthma exacerbations in adults: Systematic review and meta-analysis. Zhang, Hong Ping; Jia, Chun E.; Lv, Yan; Gibson, Peter Gerard; Wang, Gang // Allergy & Asthma Proceedings;Jul/Aug2014, Vol. 35 Issue 4, p278 

    It has proven efficacy in reducing asthma exacerbations, but the effect size of montelukast (a leukotriene receptor antagonist) for varied severity of asthma exacerbations is not systematically assessed. This study was designed to systematically explore the evidence for montelukast, as...

  • Recently approved leukotriene cuts the number of days with symptoms and the number of physician...  // Modern Medicine;Apr97, Vol. 65 Issue 4, p16 

    Reports on the effectiveness of a daily regimen of zafirlukast, a leukotriene receptor antagonist, in combination with an as-needed beta agonist in treating patients with mild-to-moderate asthma. Decline in the number of days in which the patients experienced asthmatic symptoms; Decline in the...

  • Focus on zafirlukast: A leukotriene receptor antagonist for the prophylaxis and chronic... Baldinger, Sandra L.; Shore, Eric T. // Formulary;Nov96, Vol. 31 Issue 11, p1029 

    Examines the use and effectiveness of zafirlukast, a potent and specific leukotriene receptor antagonist approved by the Food and Drug Administration (FDA) for the treatment of asthma in patients 12 years of age and older. Chemistry and pharmacology; Pharmacokinetics; Results of clinical trials...

  • Zafirlukast in Clinical Practice. Kemp, James P.; Korenblat, Phillip E.; Scherger, Joseph E.; Minkwitz, Margaret // Journal of Family Practice;Jun1999, Vol. 48 Issue 6, p425 

    BACKGROUND. Zafirlukast is an oral leukotriene receptor antagonist used in the treatment of patients with mild to moderate asthma. To investigate its effects in a clinical practice setting, we evaluated zafirlukast in a heterogeneous group of patients who had asthma of different degrees of...

  • zafirlukast. Peters, Michael // BMA A-Z Family Medical Encyclopedia;2004, p814 

    A definition of the term "zafirlukast" is presented. It refers to a leukotriene receptor antagonist. Zafirlukast is used in asthma prevention.

  • Inhaled glucocorticoids versus leukotriene receptor antagonists as single agent asthma treatment: systematic review of current evidence. Ducharme, Francine M. // BMJ: British Medical Journal (International Edition);3/22/2003, Vol. 326 Issue 7390, p621 

    Objective: To compare the safety and efficacy of anti-leukotrienes and inhaled glucocorticoids as monotherapy in people with asthma. Design: Systematic review of randomised controlled trials comparing anti-leukotrienes with inhaled glucocorticoids for 28 days or more in children and adults. Main...

  • Oral leukotriene receptor antagonist is effective in asthmatics who have moderate airflow... Nathan, Robert A. // Modern Medicine;Nov97, Vol. 65 Issue 11, p11 

    Highlights the research by Roberth A. Nathan and colleagues recommending oral leukotriene receptor antagonist zafirlukast (Accolate) to alleviate symptoms and improve the quality of life for asthma patients. Outcome of the multicenter trial conducted; Side effects; Categories of quality of life...

  • LTRAS 'as effective' as steroid inhalers. Duffin, Christian // Pulse;5/11/2011, Vol. 71 Issue 17, p6 

    The article discusses research being done on leukotriene-receptor antagonists (LTRA) as first-line therapy for patients with mild to moderate asthma which references a study published in "New England Journal of Medicine."

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sign out of this library

Other Topics